- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Optimizing Bispecific Use in Multiple Myeloma Treatment
A key opinion leader explores the integration of bispecifics into MM therapy regimens.
EP: 1.Unmet Needs and Treatment Approaches in Newly Diagnosed Multiple Myeloma
EP: 2.ASH 2023: PERSEUS Trial Overview
EP: 3.Considerations for Combination Therapy and MRD Testing in Newly Diagnosed Multiple Myeloma Patients
EP: 4.ASH 2023: Analyzing IsKia Trial
EP: 5.Examining Data from MonumenTAL-2 Study
EP: 6.Optimizing Bispecific Use in Multiple Myeloma Treatment
EP: 7.Navigating Impact of RRMM Treatment on Patient Quality of Life
EP: 8.Key RRMM-Related Takeaways from ASH 2023
This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.
When using bispecific antibodies in multiple myeloma (MM), proper sequencing with chimeric antigen receptor (CAR) T-cell therapy is important since they can target similar antigens. CAR T-cell therapy may be favored earlier given the one-and-done appeal and quality of life benefits shown in studies like CARTITUDE-4 and KarMMa. Bispecifics are now better managed with less concern about cytokine release syndrome, even allowing outpatient administration at some centers, potentially expanding community hospital access beyond academic sites.
While bispecifics don’t match CAR T-cell therapy response rates, their wider eligibility makes them an exciting option. They will also likely expand into solid tumors. However, infections remain a key long-term toxicity that requires prevention/proactive management with IgG replacement and antibiotics. Understanding optimal dosing and schedules for antibodies like talquetamab will also minimize cumulative toxicities like rash and weight loss that can impact quality of life. But with proper mitigation strategies, bispecifics have a promising future in myeloma.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
